TP53 and B-cell chronic lymphocytic leukemia: In CLL patients with TP53 aberrations, median PFS after O-ibrutinib was superior, compared with O-Clb (NR after 31 months versus 15.2 months, HR 0.14; 95%CI, 0.04-0.51) (31).